Buprenorphine as a Treatment Option for Opioid Use Disorder
|
|
|
- Cori Melton
- 5 years ago
- Views:
Transcription
1 Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital *Images used for educational purposes only. All copyrights belong to image owners*
2 Outline 1. Waiver requirements 2. Evidence base for buprenorphine in treating opioid use disorders 3. Buprenorphine pharmacology 4. Clinical use of buprenorphine
3 Outline 1. Waiver requirements 2. Evidence base for buprenorphine in treating opioid use disorders 3. Buprenorphine pharmacology 4. Clinical use of buprenorphine
4 1914: Harrison Narcotics Act 1970: Controlled Substance Act 1974: Methadone maintenance approved 2000: DATA 2000 and waiver requirements 2016: Comprehensive Addiction Recovery Act (CARA) 1800s and early 1900s: Rise of opioid addiction in the US
5 Drug Addiction Treatment Act 2000 (DATA 2000) Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment (H.R. 4365, Children s Health Act)
6 Practitioner requirements Medication requirements Physician completes 8 hours of training, and NP/PAs complete 24 hours of training Register with SAMHSA and DEA Treat no more than 30 patients (concurrently, not cumulatively) After 1 calendar year since initial approval, may increase to 100 patients (for MD/NP/PAs) As of 2016, qualifying physicians can further increase limit to 275. Have the capacity to refer patients to counseling and ancillary services Only medications approved by the US FDA for opioid dependence treatment may be used Schedule III, IV, or V only Buprenorphine/naloxone or buprenorphine Sublingual and buccal Tablets or films Implantable buprenorphine DATA2000; CARA
7 SAMHSA 2016 Number of MDs obtaining waiver each year in the US Total of 22,290 physicians completed waiver training to prescribe to 30 Total of 10,888 physicians have applied to increase capacity to Patients 100 Patients *Partial data
8 Outline 1. Waiver requirements 2. Evidence base for buprenorphine in treating opioid use disorders 3. Buprenorphine pharmacology 4. Clinical use of buprenorphine
9 % of heroin taken Buprenorphine reduces the cravings for heroin, allowing individual to focus on longer-term goals Dose Mello and Mendelson 1980
10 Illicit Opioid Use Treatment leads to reduced illicit opioid use, but relapse frequently occurs after taper Detoxification Weeks Strain, 1996
11 Remaining in treatment (nr) Even with extensive psychosocial support, difficult to stay in treatment after detoxification compared to maintenance with buprenorphine 0 deaths 4 deaths Treatment duration (days) All patients received group CBT Relapse Prevention, Weekly Individual Counseling, 3x Weekly Urine Screens, n=20 per group Kakko J, Lancet 2003
12 Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Review) Review of 31 trials and 5,430 participants Treatment retention: Mattick RP, Breen C, Kimber J, Davoli M, 2014 Buprenorphine superior to placebo at all dose ranges Buprenorphine no different than methadone, except methadone superior to buprenorphine at low doses Suppression of illicit opioid use Only high dose (>16 mg) of buprenorphine superior to placebo Buprenorphine equally effective to methadone
13 Weiss et al 2015 Long-term outcomes from POATS study (n=375) 120 Current opioid dependence Agonist treatment Abstinent from illicit opioids Days of illicit rx opioid use Baseline Month 18 Month 30 Month 42
14 Summary of evidence for buprenorphine treatment Suppression of illicit opioid use, especially at doses greater than 16 mg per day When sufficiently dosed, improved treatment retention comparable to methadone Maintenance treatment leads to superior outcomes compared to taper Taper leads to relapse in many patients despite high levels of motivation Longer-term study suggests some patients are able to maintain their abstinence without agonists while others continue to benefit from maintenance treatment
15 Outline 1. Waiver requirements 2. Evidence-base for buprenorphine in treating opioid use disorders 3. Buprenorphine pharmacology 4. Clinical use of buprenorphine
16 Chemical: Pharmacodynamics: Half-life: Active metabolites: Semi-synthetic opioid Mu-opioid receptor partial agonist, kappa-opioid antagonist 3-44 hours norbuprenorphine, buprenorphine-3-glucuronide, norbuprenorphine-3-glucuronide Tmax: Metabolism: 40 minutes to 3.5 hours N-dealkylation to norbuprenorphine via CYP3A4 Elimination: Feces, 10-30% in urine Bioavailability: IM 70%, sublingual solution 50%, sublingual tablet 30%, buccal 28%, oral 10% CSAT TIP
17 Activation of the mu-opioid receptor by endorphins leads to opioid-like effects Endorphin Opioid Receptor Pain relief Euphoria Constipation Slow breathing CSAT TIP
18 Activation of the mu-opioid receptor by heroin leads to similar effects Opioid Receptor Heroin H Pain relief Euphoria Constipation Slow breathing CSAT TIP
19 Activation of the mu-opioid receptor by methadone also leads to opioid-like effects Opioid Receptor Methadone M Pain relief Euphoria Constipation Slow breathing CSAT TIP
20 Activation of the mu-opioid receptor by buprenorphine only leads to partial opioid-like effects Buprenorphine B Opioid Receptor Pain relief Euphoria Constipation Slow breathing CSAT TIP
21 Activation of the mu-opioid receptor by naltrexone leads to no opioid-like effects Naltrexone N 2 1 CSAT TIP
22 Receptor activation (%) Buprenorphine, Methadone, and Naltrexone Methadone Full Agonist Partial Agonist Antagonist Buprenorphine Naltrexone Dose 2 2 CSAT TIP
23 Methadone blocks the effects of heroin Heroin H M Pain relief Euphoria Constipation Slow breathing CSAT TIP
24 Buprenorphine also blocks the effects of heroin B Heroin H Pain relief Euphoria Constipation Slow breathing CSAT TIP
25 Naltrexone blocks the effects of heroin Heroin H N CSAT TIP
26 High affinity + partial agonism = Potential for precipitated withdrawal H Buprenorphine B Heroin 2 6 CSAT TIP
27 Receptor activation (%) Precipitated withdrawal Administering buprenorphine while full agonists are present leads to ANTAGONIST effects Full Agonist Partial Agonist Antagonist No drug Low dose High dose CSAT TIP
28 Receptor activation (%) Precipitated withdrawal Administering buprenorphine while full agonists are NOT present leads to AGONIST effects Full Agonist Partial Agonist Antagonist No drug Low dose High dose CSAT TIP
29 Opioid Use Disorder Chronic Pain Sublingual Tablets Buprenorphine/naloxone Buprenorphine None Sublingual Films Buprenorphine/naloxone None Buccal Films Buprenorphine/naloxone Buprenorphine Transdermal None Buprenorphine Parenteral None Buprenorphine Implant Buprenorphine implant None Johnson et al 2005; SAMHSA 2016; Rosenthal et al 2013
30 Combination tablet Mono tablet Buprenorphine and naloxone in a 4:1 ratio If taken as prescribed, naloxone is minimally absorbed If injected, naloxone will produce a short (30-60 min) withdrawal reaction Only buprenorphine Reserve for pregnant patients or for those with documented allergy to naloxone Has a higher misuse liability and street value Combination tablet should be used be default CSAT TIP
31 Opioid Use Disorder Chronic Pain Sublingual Tablets Buprenorphine/naloxone Buprenorphine None Sublingual Films Buprenorphine/naloxone None Buccal Films Buprenorphine/naloxone Buprenorphine Transdermal None Buprenorphine Parenteral None Buprenorphine Implant Buprenorphine implant None Johnson et al 2005; SAMHSA 2016; Rosenthal et al 2013
32 Outline 1. Waiver requirements 2. Evidence-base for buprenorphine in treating opioid use disorders 3. Buprenorphine pharmacology 4. Clinical use of buprenorphine
33 Edwards and Koob, 2010; CSAT TIP Medication Control cravings Block other opioids Counseling Learn about addiction and recovery Relapse prevention skills and managing cravings Treatment of psychiatric co-morbidities PATIENT CARE Community supports Peer supports Sober social network Family supports
34 Medication Control cravings Block other opioids Opioid Receptor Buprenorphine B Edwards and Koob, 2010; CSAT TIP
35 Counseling Learn about addiction and recovery Relapse prevention skills and managing cravings Treatment of psychiatric co-morbidities Edwards and Koob, 2010; CSAT TIP
36 Medication medication treatment should not be withheld from patients even if specialized counseling is not offered or not available. Several multi-site studies of CBT, contingency management, and manualized drug counseling showed no benefit of these interventions above and beyond standard medical management. Edwards and Koob, 2010; CSAT TIP
37 Community supports Peer supports Sober social network Family supports Edwards and Koob, 2010; CSAT TIP
38 There are still some meetings and members who are opposed to the use of medications to treat OUD. disclosing use of buprenorphine needs to be considered carefully patients should still utilize AA/NA if they find it useful.
39 Initial assessment and patient selection Induction Early recovery and stabilization Maintenance
40 Initial assessment and patient selection Assess if outpatient treatment is appropriate Detoxification vs maintenance
41 Induction Eliminate withdrawal Avoid precipitated withdrawal
42
43 The patient should be given comfort medications (such as clonidine, trazodone, loperamide). Patient is reminded that no opioid should be used after 8-10 pm, and the induction may be tried the next day. However, prevention is the best policy
44 Early recovery and stabilization Weekly visits Medication + psychosocial supports Reduce cravings and illicit opioid use
45 There should not be an expectation that all patients will be able to abstain from all drugs or illicit opiate use during the early treatment phase.
46 Maintenance Less frequent visits Sustained recovery
47 Summary (1) - To prescribe Bup, prescriber must obtain waiver - Bup is a partial agonist - Bup has a high affinity at the Mu receptor - Just as effective as methadone - Potential to produce precipitated withdrawal - Most commonly given as a combination tablet
48 Summary (2) - Prescribe monotablet only in exceptions - Treatment = medication, counseling, social supports - 2-step initiation process - Induction will follow initiation - On-site induction is preferred
49 Unit Resources SAMHSA - Medication Assisted Treatment Drug Enforcement Administration - DEA Requirements for DATA Waived Physicians (DWPs) Buprenorphine suppresses heroin use by heroin addicts (Mello NK & Mendelson JH, 1980) 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial (Kakko et. al, 2003) SAMHSA - TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Quick Guide For Physicians Based on TIP 40 (pdf) Clinical Opiate Withdrawal Scale Neurobiology of dysregulated motivational systems in drug addiction (Edwards and Koob, 2010)
Opioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
Module 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone
Module 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone History of Medical Practice for Opioid Addiction in the U.S. Physicians had been liberal prescribers of morphine in late 1800s/early
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
Treatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
Building capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
Medication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
Opioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
Opioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
Substitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
Disclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE
BUPRENORPHINE UPDATE Christian J. Teter, Pharm.D., BCPP Associate Professor, Psychopharmacology College Of Pharmacy, University Of New England Portland, ME E-Mail: cteter@une.edu Image Source: pubchem.ncbi.nlm.nih.gov
Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
Buprenorphine Access in California
Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical
Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
Buprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
Medication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
Appendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
MAT 101: TREATMENT OF OPIOID USE DISORDER
MAT 101: TREATMENT OF OPIOID USE DISORDER WITH SPECIAL EMPHASIS ON BUPRENORPHINE/NALOXONE ICADD May 22, 2018 Alicia Carrasco, MD Debby Woodall, LCSW, ACADC Magni Hamso, MD, MPH Terry Reilly Health Services
Public Policy Statement on the Regulation of Office-Based Opioid Treatment
Public Policy Statement on the Regulation of Office-Based Opioid Treatment Background Office-based opioid treatment (OBOT) commonly refers to outpatient treatment services provided outside of licensed
Medication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
Opioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
Opioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
IntNSA Webinar Series
BUPRENORPHINE CLINIC: A MULTIDISCIPLINARY MODEL FOR OPIOID MAINTENANCE THERAPY Stephen Strobbe, PhD, RN, NP, PMHCNS-BC, CARN-AP Monday, June 4, 2012 IntNSA Webinar Series Funding for this webinar was made
Virginia Opioid Addiction ECHO*
Virginia Opioid Addiction ECHO* Project ECHO: July 27th *ECHO: Extension of Community Healthcare Outcomes Agenda Agenda Agenda Introductions Clinical Director Administrative Medical Director ECHO Hubs
Medication Assisted Treatment:
Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications
Opioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
Opioid Dependence 101 and Medication Assisted Treatment
Opioid Dependence 101 and Medication Assisted Treatment Dr. Joji Suzuki Director of the Division of Addiction Psychiatry, Brigham & Women s Hospital Assistant Professor of Psychiatry, Harvard Medical School
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders
The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,
Serious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
Management of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
Opioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
National Opioid Treatment Guideline Dr. Ronald Lim
National Opioid Treatment Guideline Dr. Ronald Lim (MD, CCFP, DFASAM, ABAM(D), FISAM, CCSAM, MRO) Clinical Assistant Professor, Department of Psychiatry and Family Practice Cumming School of Medicine University
The role of behavioral interventions in buprenorphine treatment of opioid use disorders
The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies
Identification and Treatment of Opioid Use Disorders in Primary Care Settings
Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine
Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.
Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction
OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM
OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian
Opioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
BUPRENORPHINE and Office-Based Treatment of Opioid Use Disorder
BUPRENORPHINE and Office-Based Treatment of Opioid Use Disorder Stephen A. Wyatt, DO Anthony Dekker, DO William Morrone, DO Funding for this initiative was made possible (in part) by Providers Clinical
Vivitrol Vs. Suboxone
Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
Steven Prakken MD Director Medical Pain Service Duke Pain Medicine
Steven Prakken MD Director Medical Pain Service Duke Pain Medicine Misuse Abuse Addiction Total Pain Population Webster LR, Webster RM. Pain Med. 2005;6(6):432-442. DSM IV Abuse defined as 2 elements
Opioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
Medication Treatment and Opioid Use Disorder
Medication Treatment and Opioid Use Disorder Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBOT-B Boston Medical Center Disclosures I have no disclosures
Management Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry
The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic
It s Not Just One More Thing! Overcoming Obstacles for Buprenorphine Treatment by Residents, Faculty and Programs
It s Not Just One More Thing! Overcoming Obstacles for Buprenorphine Treatment by Residents, Faculty and Programs Ken Saffier, MD Maureen Strohm, MD May 7, 2017 Disclosures Ken Saffier, MD, has nothing
Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model
Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased
Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US,
Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US, 1999 21 8 Rates of Prescription Painkiller Sales, Deaths, and Substance Abuse Treatment Admissions (1999 21) 7 Rate 6 5 4 3 Sales per
Psychosocial Treatments for Opioid Use Disorder Overview
Psychosocial Treatments for Opioid Use Disorder Overview Nalan Ward, MD Director Outpatient Addiction Services Department of Psychiatry Massachusetts General Hospital *Images used for educational purposes
Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
MAT - ICAAD 2018 Ron Jackson, MSW, LICSW
The ATTC Network Ten Regional Centers northwest@attcnetwork.org www.attcnetwork.org/northwest phone. 206-685-4419 1107 NE 45 th St, Ste 120, Seattle, WA 98105 http://attcnetwork.org/northwest U.S. Opioid
GOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
Quick Guide. For Physicians. Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Quick Guide For Physicians Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Buprenorphine Clinical Guide Contents Why a Quick Guide?....................
ROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
Revised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement
Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement TANNER NISSLY DO, BOB LEVY MD FASAM, MICHELE MANDRICH MSW, CMPE AS YOU ENTER, PLEASE SET UP TO PARTICIPATE IN OUR POLL EVERYWHERE
Opioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.
Opioid Use Disorders as a Brain Disease Why MAT is so important Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of Social Work University of Washington Organization Name: CareOregon Course Title:
The CARA & Buprenorphine Prescribing for APNs & PAs
The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,
Optimizing Suboxone in Opioid Addicts
Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org
Treating Opioid Use Disorders: An Update for Counselors and Other Providers
Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL
Latest Research on Addiction and Treatment
Latest Research on Addiction and Treatment Joshua D Lee MD MSc joshua.lee@nyumc.org / @DrJoshuaDLee Associate Professor NYU School of Medicine, Department of Population Health Disclosures, LeeJD Grants:
The Rising Tide of Prescription Opioid Use Disorders and Current Treatment Options
The Rising Tide of Prescription Opioid Use Disorders and Current Treatment Options Michelle R. Lofwall, MD UK Dept of Psychiatry November 4, 2008 Outline for Today s Talk Past & current state of affairs
Dr. Renner receives honoraria from Reed Medical Education
Substance Use Disorders Symposium on Men s Health Massachusetts Medical Society June 17, 2010 John A. Renner, Jr., M.D. John A. Renner Jr., MD DISCLOSURES Johnson & Johnson Stock Holder Dr. Renner receives
for Opioid Dependence Buprenorphine/Naloxone Bunavail TM Suboxone Film Zubsolv Policy Number: MCP-072 Revision Date(s): 2/25/13; 4/4/17
Subject: Buprenorphine/Naloxone and Buprenorphine Original Effective Date: 8/26/09 for Opioid Dependence Buprenorphine/Naloxone Bunavail TM Suboxone Film Zubsolv generic Buprenorphine/Naloxone sublingual
Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction
Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction Thank you, Chairman Rogers, for holding this important Summit and helping to bring attention
AGENDA U.S. SURGEON GENERAL, VIVEK MURTHY MD 2/5/2019
FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5
U.S. SURGEON GENERAL, VIVEK MURTHY MD
FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5
Medication for the Treatment of Addiction (MAT)
Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication
Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
Buprenorphine and MAT 101
Buprenorphine and MAT 101 Why is Medication Assisted Treatment so Important for Recovery? KEN SAFFIER, MD 7 TH ANNUAL INTEGRATION SUMMIT DECEMBER 8, 2016 Disclosures: u Ken Saffier, MD, has nothing to
Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations
Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations Dr. Ajeet Sidana Department of Psychiatry Government Medical College & Hospital Chandigarh Scope of Presentation
Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018
Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018 Judith Martin, MD, Medical Director of Substance Use Services, San Francisco Department of Public Health Webinar
Long term treatment for opioid dependence Antagonist therapy
Long term treatment for opioid dependence Antagonist therapy Treatment of Opioid Dependence Antagonist treatment Naltrexone Naltrexone (NTX) synthesized in 1965 Eliminate drug carving and prevent relapse
Relapsing Late in Life: Opioid use disorder in a geriatric patient
Relapsing Late in Life: Opioid use disorder in a geriatric patient Kerry Sheets, MD Geriatric Medicine Fellow, HCMC MAGIC Annual Conference, 11/9/2018 Outline Case presentation Epidemiology of opioid use/misuse
Buprenorphine: how to use it right
Drug and Alcohol Dependence 70 (2003) S59/S77 Review Buprenorphine: how to use it right Rolley E. Johnson a,1, *, Eric C. Strain a, Leslie Amass b a Department of Psychiatry and Behavioral Sciences, Johns
Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
Dr Alistair Dunn. General Practitioner Whangarei
Dr Alistair Dunn General Practitioner Whangarei 1982 Temgesic = Buprenorphine Sublingual opiate analgesic 0.2 mg Popular drug of abuse 1991 Temgesic NX = Bup & Nalxone Nalxone added to deter abuse 1999
Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers
Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers Marwan S. Haddad, M.D. Community Health Center, Inc. Connecticut September 16, 2008 Community Health Center, Inc.